Skip to content
Inciteful Med

Research, Clinical Trials, and Future Treatments

Last updated:

While there is currently no cure for Charcot-Marie-Tooth (CMT) disease, active research is focused on treating its genetic causes. Clinical trials are exploring promising approaches like gene silencing, CRISPR editing, and drugs like PXT3003, while Vitamin C is no longer recommended.

Key Takeaways

  • • Researchers are shifting focus from simply managing CMT symptoms to directly targeting the underlying genetic causes of the disease.
  • • PXT3003, an experimental drug for CMT1A, remains an active area of research despite a recent setback in its Phase 3 clinical trial.
  • • Emerging gene therapies for CMT include gene silencing (ASOs and siRNA), CRISPR gene editing, and targeted gene replacement.
  • • Extensive human clinical trials have proven that high doses of Vitamin C do not treat CMT and can increase the risk of kidney stones.
  • • Patients can actively support CMT research by joining contact registries like the Inherited Neuropathies Consortium (INC) or GRIN.

The landscape of research into Charcot-Marie-Tooth disease (CMT) is more active today than ever before. While there is currently no cure, scientists are moving beyond just managing symptoms and are now testing treatments that aim to fix the underlying genetic cause of the disease [1][2].

The Clinical Trial Landscape: PXT3003

For those with CMT1A (the most common form), a drug called PXT3003 has been highly discussed [3][4].

  • How it works: CMT1A is caused by having an extra copy of the PMP22 gene, which leads to a toxic overproduction of the PMP22 protein [5][6]. PXT3003 is a combination of three existing medications (baclofen, naltrexone, and sorbitol) that work together to “turn down the volume” on that gene, reducing the protein to more normal levels [7][8].
  • Current Status: PXT3003 has been the most advanced drug in development for CMT1A. However, research is complex, and the drug recently faced a setback when its latest Phase 3 trial (the PREMIER trial) missed its primary endpoint, showing no significant difference from a placebo [9][10]. While this was disappointing, PXT3003 remains an active area of ongoing research, and scientists are using the trial data to better understand how to treat the disease [11].

Emerging “Gene Silencing” and Gene Therapy

Beyond pills, researchers are developing “cutting-edge” technologies to correct the genetic root of CMT [5][2].

  • ASOs and siRNA: These are like “genetic erasers” designed to find the messenger molecules (mRNA) that tell your body to make too much PMP22 and destroy them before the protein is ever made [5][12].
  • CRISPR: This “gene editing” technology is in the very early stages of research but aims to literally cut out the extra copy of the gene [13][14].
  • Gene Replacement: For types like CMTX1, where a gene is missing or broken, researchers are testing ways to “deliver” a healthy copy of the gene directly into the nerves using a harmless virus [2][15].

The Vitamin C Myth

For years, it was thought that high doses of Vitamin C (ascorbic acid) could treat CMT1A because it showed success in mouse studies [16]. However, five major clinical trials involving hundreds of human patients worldwide proved that Vitamin C does not improve the disease course in humans [16][17]. Doctors now recommend against taking massive doses of Vitamin C for CMT, as it provides no benefit and can cause side effects like kidney stones [16].

How to Get Involved

Clinical trials cannot happen without patients. You can play a vital role in finding a cure by:

  1. Joining a Registry: Sign up for the Inherited Neuropathies Consortium (INC) contact registry or the Global Registry for Inherited Neuropathies (GRIN). These registries notify you when a trial matches your specific subtype [18][19].
  2. Visiting a Center of Excellence: Many trials are only conducted at specialized CMT clinics.
  3. Checking ClinicalTrials.gov: This is the official database for all active research studies worldwide. For example, the NCT01193088 study is currently looking for CMT1A patients to help identify “modifier genes” that affect how the disease progresses.

Frequently Asked Questions

What is the current status of the PXT3003 drug for CMT1A?
PXT3003 is an experimental combination drug designed to lower the harmful overproduction of the PMP22 protein in CMT1A. Although it recently missed its primary goal in a Phase 3 clinical trial, researchers are still analyzing the data and using it to guide future treatment development.
Is gene therapy an option for treating Charcot-Marie-Tooth disease?
Yes, scientists are developing several gene-based therapies to target the root cause of CMT. These include gene silencing to stop the production of harmful proteins, CRISPR gene editing to remove extra gene copies, and gene replacement to deliver healthy genes into the nerves.
Does Vitamin C help treat CMT?
No, high doses of Vitamin C do not improve the progression of CMT. While early animal studies looked promising, multiple large human trials proved it is ineffective. Doctors advise against taking massive doses of Vitamin C because it offers no benefit and can cause kidney stones.
How can I participate in a CMT clinical trial?
The best way to find a trial is to join a patient registry like the Inherited Neuropathies Consortium (INC) or the Global Registry for Inherited Neuropathies (GRIN). You can also search the database at ClinicalTrials.gov or consult a specialized CMT Center of Excellence.

Questions for Your Doctor

  • • Based on my specific genetic subtype, am I a candidate for any current clinical trials or upcoming gene therapy studies?
  • • Are there any research centers near me that are part of the Inherited Neuropathies Consortium (INC)?
  • • Should I have a skin biopsy or a baseline MRI to track my 'biomarkers' for future research opportunities?
  • • Can you help me understand the results of the Vitamin C trials and why high doses are no longer recommended for CMT1A?

Questions for You

  • • Am I currently enrolled in a patient registry, such as the CMTA PatientsLikeMe registry or the Global Registry for Inherited Neuropathies (GRIN)?
  • • How much time and travel am I willing to commit to participating in a clinical trial?
  • • Am I comfortable with the idea of 'early-stage' research, like a Phase 1 or Phase 2 trial, or would I prefer to wait for more established treatments?
  • • Do I have an up-to-date copy of my genetic testing and recent nerve conduction studies to share with trial coordinators?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Charcot-Marie-Tooth Disease: Historical Evolution and Present Understanding].

    Yano C, Takashima H

    Brain and nerve = Shinkei kenkyu no shinpo 2025; (77(11)):1176-1184 doi:10.11477/mf.188160960770111176.

    PMID: 41233175
  2. 2

    AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.

    Kagiava A, Karaiskos C, Richter J, et al.

    Gene therapy 2021; (28(10-11)):659-675 doi:10.1038/s41434-021-00250-0.

    PMID: 33692503
  3. 3

    Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease.

    Pisciotta C, Pareyson D

    Neuromuscular disorders : NMD 2023; (33(8)):627-635 doi:10.1016/j.nmd.2023.07.001.

    PMID: 37455204
  4. 4

    Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives.

    Pisciotta C, Saveri P, Pareyson D

    Brain sciences 2021; (11(11)) doi:10.3390/brainsci11111447.

    PMID: 34827446
  5. 5

    Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future.

    Boutary S, Echaniz-Laguna A, Adams D, et al.

    Translational research : the journal of laboratory and clinical medicine 2021; (227()):100-111 doi:10.1016/j.trsl.2020.07.006.

    PMID: 32693030
  6. 6

    Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

    Prukop T, Stenzel J, Wernick S, et al.

    PloS one 2019; (14(1)):e0209752 doi:10.1371/journal.pone.0209752.

    PMID: 30650121
  7. 7

    Downregulation of PMP22 ameliorates myelin defects in iPSC-derived human organoid cultures of CMT1A.

    Van Lent J, Vendredy L, Adriaenssens E, et al.

    Brain : a journal of neurology 2023; (146(7)):2885-2896 doi:10.1093/brain/awac475.

    PMID: 36511878
  8. 8

    Charcot‑Marie‑Tooth type 1A drug therapies: role of adenylyl cyclase activity and G‑protein coupled receptors in disease pathomechanism.

    Kiepura AJ, Kochański A

    Acta neurobiologiae experimentalis 2018; (78(3)):198-209.

    PMID: 30295677
  9. 9

    A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.

    Attarian S, Young P, Brannagan TH, et al.

    Orphanet journal of rare diseases 2021; (16(1)):433 doi:10.1186/s13023-021-02040-8.

    PMID: 34656144
  10. 10

    A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.

    Mandel J, Bertrand V, Lehert P, et al.

    Orphanet journal of rare diseases 2015; (10()):74 doi:10.1186/s13023-015-0293-y.

    PMID: 26070802
  11. 11

    The current status of Charcot-Marie-Tooth disease type 1 A treatment.

    Qi H, Wang X, Wu B, et al.

    Acta neurologica Belgica 2025; (125(6)):1525-1533 doi:10.1007/s13760-025-02881-1.

    PMID: 40864398
  12. 12

    PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.

    Zhao HT, Damle S, Ikeda-Lee K, et al.

    The Journal of clinical investigation 2018; (128(1)):359-368.

    PMID: 29202483
  13. 13

    AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells.

    Yoshioka Y, Taniguchi JB, Homma H, et al.

    Communications medicine 2023; (3(1)):170 doi:10.1038/s43856-023-00400-y.

    PMID: 38017287
  14. 14

    A systematic review of CRISPR applications in demyelinating peripheral nervous system disorders.

    Mariki A, Kohlmeier KA, Mousavi SM, Shabani M

    Regenerative medicine 2025; (20(11)):653-662 doi:10.1080/17460751.2025.2574198.

    PMID: 41108054
  15. 15

    A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X.

    Christou M, Sargiannidou I, Papacharalambous R, et al.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2025; (22(3)):e00568 doi:10.1016/j.neurot.2025.e00568.

    PMID: 40055046
  16. 16

    [Ascorbic Acid and Charcot-Marie-Tooth Disease].

    Noto Y

    Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(10)):1241-6 doi:10.11477/mf.1416200289.

    PMID: 26450076
  17. 17

    Caveats in the Established Understanding of CMT1A.

    Li J

    Annals of clinical and translational neurology 2017; (4(8)):601-607 doi:10.1002/acn3.432.

    PMID: 28812050
  18. 18

    Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene.

    Sanmaneechai O, Feely S, Scherer SS, et al.

    Brain : a journal of neurology 2015; (138(Pt 11)):3180-92 doi:10.1093/brain/awv241.

    PMID: 26310628
  19. 19

    The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

    Johnson NE, Heatwole C, Creigh P, et al.

    Annals of neurology 2018; (84(2)):225-233 doi:10.1002/ana.25282.

    PMID: 30014533

This page provides updates on CMT research and clinical trials for informational purposes only. Always consult your neurologist before making any treatment decisions or enrolling in a research study.

Stay up to date

Get notified when new research about Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy is published.

No spam. Unsubscribe anytime.